drugset / Trial / NCT05746481
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
NaSingle-groupOpen-labelTreatment
Summary
This clinical trial is aimed at the evaluation of the safety and clinical activity of tiragolumab in combination with atezolizumab with or without chemotherapy in the first line treatment of metastatic non-squamous NSCLC patients with asymptomatic untreated brain metastases.
Timeline
- Start
- 2023-08-10
- Primary completion
- 2024-08-19
- Completion
- 2025-11-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tiragolumab | Monoclonal antibody | 600 mg | Intravenous |
| Background | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Background | Carboplatin | Small molecule | — | Other |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |